Adlai Nortye Biopharma Co., Ltd.

This is an early-stage trial testing a new oral drug called AN9025 in people with advanced solid tumors that have specific RAS gene mutations. The main goals are to find a safe dose, understand how the body processes the drug, and see if it shows any early signs of fighting the c…

This is the first study in people to test a new oral drug called AN4005 for patients with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe and tolerable dose by giving the drug to small groups of patients at increas…